| Reaction Details |
|---|
 | Report a problem with these data |
| Target | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A |
|---|
| Ligand | BDBM484559 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | Enzyme Assay |
|---|
| Ki | 1.60±n/a nM |
|---|
| Citation |  Arasappan, A; Cox, JM; Debenham, JS; Hussain, Z; Li, D; Meng, D; Raghavan, S Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors US Patent US11028092 Publication Date 6/8/2021 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A |
|---|
| Name: | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A |
|---|
| Synonyms: | 3',5'-cyclic phosphodiesterase | PDE9A | PDE9A_HUMAN | Phosphodiesterase 9A | Phosphodiesterase 9A (PDE9) | Phosphodiesterase 9A (PDE9A) |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 68488.40 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | O76083 |
|---|
| Residue: | 593 |
|---|
| Sequence: | MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAM
VSIDPTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGLEQPRRE
GAFESGQVEPRPREPQGCYQEGQRIPPEREELIQSVLAQVAEQFSRAFKINELKAEVANH
LAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHKKLTPRRDV
PTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLF
CVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYN
NTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFKQIRQGMITLI
LATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKCCDISNEVRPMEVAEPWVDCL
LEEYFMQSDREKSEGLPVAPFMDRDKVTKATAQIGFIKFVLIPMFETVTKLFPMVEEIML
QPLWESRDRYEELKRIDDAMKELQKKTDSLTSGATEKSRERSRDVKNSEGDCA
|
|
|
|---|
| BDBM484559 |
|---|
| n/a |
|---|
| Name | BDBM484559 |
|---|
| Synonyms: | US10934294, Example 80 | US10934294, Example 81 | US11028092, Example 81 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C23H20FN9O |
|---|
| Mol. Mass. | 457.463 |
|---|
| SMILES | CC(c1cnc(nc1)C1CC1)n1nc(C#N)c2c1nc([nH]c2=O)[C@H]1CC[C@@H]1c1ncc(F)cn1 |r| |
|---|
| Structure | 
|
|---|
Search and Browse
